DICYNONE

Indications

• Menorrhagia
• Abnormal uterine bleeding
• Prevention of bleeding during surgical procedures
• Post-operative bleeding

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Etamsylate enhances the stability of capillaries and reduces their permeability. It promotes platelet aggregation and has a role in the coagulation cascade, though its precise mechanism is not fully understood.

Pharmacodynamics

Etamsylate acts by stabilizing the endothelial cells of capillaries, which helps to prevent leakage of plasma proteins and fluid into tissues, thereby reducing bleeding. The drug has been shown to be effective in various clinical settings, particularly in managing heavy menstrual bleeding.

Pharmacokinetics

Etamsylate is rapidly absorbed after oral administration and reaches peak plasma concentrations within 1 to 3 hours. It is metabolized in the liver, with a significant portion excreted unchanged in urine. The elimination half-life of etamsylate is approximately 3 hours, allowing for flexible dosing schedules.

Adverse effects

• Gastrointestinal disturbances
• Allergic reactions
• Headache
• Dizziness

Precautions

• Use with caution in patients with a history of hypersensitivity to etamsylate or any of its components
• Monitor for signs of bleeding in patients with coagulopathies

Pregnancy

Etamsylate should only be used during pregnancy if the benefits outweigh the risks, as safety in human pregnancy has not been established.

Breast-feeding

Etamsylate is excreted in breast milk, and caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Injectable solution